| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-09-18 | Cubist Pharmaceuticals (USA - MA) | Establishment of a new subsidiary in the EU | ||||
| 2014-09-18 | Boehringer Ingelheim (Germany) CureVac (Germany) | CV9202 | lung cancer | development licensing |
Cancer - Oncology | Development agreement |
| 2014-09-18 | Merck Serono, a Merck KGaA company (Germany) | chief executive officer | nomination | Nomination | ||
| 2014-09-17 | PTC Therapeutics (USA - NJ) | international headquarters in Dublin | Duchenne muscular dystrophy | nomination - opening of new premises | Rare diseases - Genetic diseases - Neuromuscular diseases | Nomination |
| 2014-09-17 | Sanofi (France) MyoKardia (USA - CA) | targeted therapeutics | cardiomyopathies | development |
Cardiovascular diseases - Genetic diseases | Development agreement |
| 2014-09-17 | OncoDNA (Belgium) Istomedica (Greece) | OncoDEEP DX and Clinical cancer panels | Cancer - Oncology | Distribution agreement | ||
| 2014-09-17 | Merck Serono, a Merck KGaA company (Germany) Sutro Biopharma (USA - CA) | antibody drug conjugates | licensing |
Cancer - Oncology | Licensing agreement | |
| 2014-09-17 | Merck&Co (USA - NJ) Sun Pharmaceuticals (India) | tildrakizumab | psoriasis | licensing | Autoimmune diseases - Dermatological diseases - Inflammatory diseases | Licensing agreement |
| 2014-09-16 | Pharnext (France) Hereditary Neuropathy Foundation (USA - NY) | Charcot-Marie-Tooth disease | collaboration | Rare diseases - Genetic diseases - Neurological diseases | Collaboration agreement | |
| 2014-09-16 | Recordati (Italy) Plethora (UK) | PSD502 (topical spray formulation of lidocaine and prilocaine) | premature ejaculation | Sexual disorders - Urological diseases | Commercialisation agreement | |
| 2014-09-16 | Eisai (Japan) St. Jude Children\'s Research Hospital (USA - TN) Medicines for Malaria Venture (Switzerland) | new antimalarial medicines including SJ733 | malaria | Infectious diseases - Parasitic diseases | R&D agreement | |
| 2014-09-16 | Eisai (Japan) the Broad Institute (USA - MA) | new antimalarial medicines | malaria | Infectious diseases - Parasitic diseases | R&D agreement | |
| 2014-09-16 | Pfizer (USA - NY) MedGenesis Therapeutix (Canada) | glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology | Parkinson's Disease | licensing |
Neurodegenerative diseases | Licensing agreement |
| 2014-09-16 | Denovo Biopharma (USA - CA) Eli Lilly (USA - IN) | enzastaurin | diffuse large B-cell lymphoma | product acquisition |
Cancer - Oncology | Product acquisition |
| 2014-09-16 | University of Iowa (USA - IA) IBA (Belgium) | ultra-high precision Intensity Modulated Proton Therapy, Dynamic Collimation System | R&D agreement | |||
| 2014-09-16 | Dimension Therapeutics (USA - MA) | chief executive officer | nomination | Rare diseases | Nomination | |
| 2014-09-15 | Evotec (Germany) the Jain Foundation (USA - WN) | cell-based high throughput screening assay, screening of compound libraries | dysferlinopathy | collaboration R&D |
Rare diseases - Genetic diseases - Neuromuscular diseases | Collaboration agreement |
| 2014-09-15 | ImmunoGen (USA - MA) | Cancer - Oncology | Nomination | |||
| 2014-09-15 | Akashi Therapeutics (USA - MA) Tonus Therapeutics (USA - NY) | GsMTx-4 | Duchenne muscular dystrophy | Genetic diseases - Neuromuscular diseases - Rare diseases | Product acquisition | |
| 2014-09-15 | Epizyme (USA - MA) | Cancer - Oncology | Nomination |
